Australia Stock Exchange release from FIREBRICK PHARMA : Nasodine COVID-19 trial receives SAHPRA approval
31/01/2022 22:50
Australia Stock Exchange release from FIREBRICK PHARMA FRE.AX : Nasodine COVID-19 trial receives SAHPRA approval
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement